Large gap with delayed quotes
|
Last quote
08/30/2025
-
02:00:00
|
Bid
08/29/2025 -
21:59:59
|
Bid Volume |
Ask
08/29/2025 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
27.57
-0.48
(
-1.71% )
|
27.59
|
5,700 |
27.61
|
1,800 |
Analysis date: 29.08.2025
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 11.07.2025.
Interest
Very strong
Very strong
Four stars since 18.07.2025.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 30.05.2025 at a price of 16.93.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 11.07.2025.
4wk Rel Perf
44.09%
44.09%
The four-week dividend-adjusted overperformance versus SP500 is 44.09%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.60%.
Mkt Cap in $bn
3.48
3.48
With a market capitalization between $2 & $8bn, APELLIS PHARMS. is considered a mid-cap stock.
G/PE Ratio
3.74
3.74
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
16.01
16.01
The estimated PE is for the year 2029.
LT Growth
59.90%
59.90%
The annualized growth estimate is for the current year to 2029.
Avg. Nb analysts
15
15
Over the last seven weeks, an average of 15 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
73
73
For 1% of index variation, the stock varies on average by 0.73%.
Correlation
0.25
0.25
Stock movements are strongly independent of index variations.
Value at Risk
10.96
10.96
The value at risk is estimated at USD 10.96. The risk is therefore 39.75%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
22.04.2022
22.04.2022